Bristol-Myers Squibb moves cardiac ultrasound agent closer to European market:
This article was originally published in Clinica
Executive Summary
Bristol-Myers Squibb (BMS) has moved a major step closer to gaining European market clearance for its echocardiography contrast agent, Luminity (perflutren 150 microlitres/ml solution). The EU's Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission grant a marketing authorisation for use of the product in patients in whom non-contrast echocardiography is suboptimal and who have suspected or established coronary artery disease. The ultrasonic properties of the perflutren-containing lipid microspheres generated after activation of Luminity are very different from those of soft tissue, enhancing blood echogenicity and increasing contrast between blood and the surrounding tissues during echocardiography.
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.